Digital Health News · Nov 2025
Covers the funding round and the company’s expansion into robotic cancer diagnostics.
Robotic Automation for cancer diagnostics - Robotic Microscopes &…
Public company, workplace, funding, and market signals
Morphle Labs is a medical device company building AI-enabled digital pathology and laboratory automation systems for cancer diagnostics, centered on robotic microtomy and whole-slide imaging workflows.
Primary product
RoboTome robotic microtome
Founded
2017
Headquarters
New York, NY, United States
Team size
80-90
Industry
Medical Device
Sub-industry
digital pathology automation
Offices
0 jobs at Morphle Labs
Check back later for new openings
Business model
Stage
Series A
Total raised
$7.5M
Latest round
Series A · Nov 2025
Latest amount
$5M
Founders
Founder CTO
Investors
Engineering-heavy, product-first culture that emphasizes hardware/software integration, fast iteration, precision manufacturing, and solving bottlenecks in cancer diagnostics.
Compensation
No public salary bands or compensation details were found in the retrieved sources; the job posting emphasized benefits and role requirements rather than pay.
Benefits
Pricing
Quote-based enterprise pricing; product pages include 'Instant Quote' and some public entry-price signals for selected scanners.
Differentiators
Technology
Customers
Competitors
Estimated revenue
Public sources conflict: Inc42 reports FY25 revenue of ₹17.9 Cr (~$2.1M), while third-party profile pages estimate revenue as high as about $9.2M ARR; a cautious public range is roughly $2M-$9M annually.
Estimated monthly visits
9.7K
Traffic estimate as of Jul 2026
Digital Health News · Nov 2025
Covers the funding round and the company’s expansion into robotic cancer diagnostics.
Business Standard · Nov 2025
Covers Morphle Labs' $5M Series A led by Inflexor Ventures and its plans to scale RoboTome and MorphoLens.
Inc42 · Nov 2025
Highlights the company’s Series A, platform products, and global expansion plans.
Economic Times B2B · Nov 2025
Describes the company’s Series A, flagship RoboTome product, and growth plans.
YourStory · Nov 2025
Reports the Series A fundraise and the company's cancer diagnostics automation focus.